Guerbet SA represents a set of core values and a corporate philosophy that underpin its operations. The company is committed to innovation, constantly striving to develop and deliver cutting-edge medical imaging solutions. Guerbet SA is driven by a strong sense of responsibility towards patients, healthcare professionals, and the environment. The company believes in fostering a culture of excellence, teamwork, and diversity, enabling employees to thrive and contribute to its overall success. By prioritizing patient safety, sustainable development, and ethical business practices, Guerbet SA aims to make a positive impact on the healthcare industry while ensuring optimum outcomes for all stakeholders.

Guerbet SA is primarily present in several countries and regions. With its headquarters in France, Guerbet has a strong presence in Europe where it operates in countries like Germany, Italy, Spain, and the United Kingdom. Additionally, the company has expanded its reach to North America, specifically in the United States and Canada. Guerbet also has a significant presence in the Asia-Pacific region, including countries like China, Japan, South Korea, and Australia. With its global operations, Guerbet SA aims to serve a diverse range of customers and establish itself as a leading player in the pharmaceutical and medical imaging sectors.

Guerbet SA, a leading global medical imaging company, has achieved several significant milestones. In recent years, the company has expanded its product portfolio, launching innovative imaging solutions to meet the evolving needs of healthcare professionals. One of its remarkable milestones was the successful development and launch of Lipiodol® Ultra-Fluid, a versatile contrast agent widely used in interventional radiology. Guerbet SA has also expanded its presence internationally, strengthening its market position and establishing strategic collaborations with key stakeholders. Furthermore, the company has received regulatory approvals for its new diagnostic imaging products, enhancing its ability to deliver state-of-the-art solutions to customers worldwide. Guerbet SA's continuous focus on innovation and strategic growth has propelled its success in the medical imaging industry.

Guerbet SA is a renowned pharmaceutical company specializing in the development, manufacturing, and distribution of medical imaging contrast agents. Founded in 1926 by Louis Guerbet, the company has a rich history and decades of experience in the healthcare industry. Guerbet SA initially focused on the production of X-ray film and photographic products before shifting its focus to contrast agents. Over the years, the company has expanded its global presence, providing innovative and effective contrast agents for various diagnostic imaging procedures. With a commitment to research and development, Guerbet SA continues to play a significant role in enhancing medical imaging technologies worldwide.

The main competitors of Guerbet SA in the market include companies such as Bayer AG, Bracco Imaging, General Electric Company, and Lantheus Medical Imaging.

Guerbet SA is primarily active in the pharmaceutical and medical imaging industries.

The business model of Guerbet SA revolves around the development, manufacturing, and commercialization of medical imaging contrast agents and solutions. Guerbet specializes in products used in diagnostic and interventional imaging, catering to radiologists and imaging professionals worldwide. The company focuses on providing innovative and safe contrast agents used in computed tomography (CT) scans, magnetic resonance imaging (MRI), and X-ray procedures. Guerbet aims to enhance the quality, efficiency, and safety of radiology while striving for sustainable development. Through its comprehensive product portfolio and commitment to research and development, Guerbet SA seeks to meet the evolving needs of the healthcare industry and improve patient care.

Guerbet KGV ir 9,56.

Guerbet KUV ir 0,36.

AlleAktien kvalitātes vērtējums Guerbet ir 2/10.

gaidāmā Guerbet apgrozījums ir 862,34 milj. EUR.

gaidāmā Guerbet peļņa ir 32,78 milj. EUR.

Guerbet SA is a French company specializing in medical imaging and contrast agents. Their business model is based on the production and distribution of medical contrast agents, as well as the development of solutions for medical imaging. The company was founded in 1901 and is headquartered in Villepinte, France. They have divisions in Imaging Solutions, Interventional Imaging, and Medical Devices. Guerbet SA is a leading provider of contrast agents globally and invests in research and development to continually improve their products.

Guerbet izmaksā dividendes 1,70 EUR, kas tiek izmaksātas reizes gadā.

Dividendes pašlaik nevar aprēķināt Guerbet vai uzņēmums nedod dividendes.

Guerbet ISIN ir FR0000032526.

Guerbet WKN ir 870481.

Guerbet simbols ir GBT.PA.

Pēdējo 12 mēnešu laikā Guerbet maksāja dividendes 1,00 EUR apmērā. Tas atbilst aptuveni 4,03 % dividendes ražībai. Nākamajos 12 mēnešos Guerbet plāno maksāt dividendes 0,93 EUR apmērā.

Guerbet pašreizējā dividendu rentabilitāte ir 4,03 %.

Guerbet maksā dividendes ceturksnī. Tās tiek izmaksātas mēnešos jūlijs, augusts, jūlijs, augusts.

Guerbet pēdējo 23 gadu laikā katru gadu izmaksāja dividendes.

Nākamajiem 12 mēnešiem tiek prognozētas dividendes apmērā 0,93 EUR. Tas atbilst dividendes ražībai 3,72 %.

Guerbet tiek piešķirts nozarei "Veselība".

Lai saņemtu pēdējo dividendu Guerbet apmērā 0,5 EUR, kas tika izmaksāta 3.07.2024., tev akcija bija jāpatur depozītā līdz Ekss dienai, kas bija 1.07.2024..

Pēdējās dividendes izmaksa notika 3.07.2024..

Gadā 2023, Guerbet izmaksāja 1,7 EUR dividendes.

Guerbet dividendes tiek izmaksātas EUR.